MA33904B1 - Utilisation d'un agent de modification d'hormones surrénaliennes - Google Patents

Utilisation d'un agent de modification d'hormones surrénaliennes

Info

Publication number
MA33904B1
MA33904B1 MA35039A MA35039A MA33904B1 MA 33904 B1 MA33904 B1 MA 33904B1 MA 35039 A MA35039 A MA 35039A MA 35039 A MA35039 A MA 35039A MA 33904 B1 MA33904 B1 MA 33904B1
Authority
MA
Morocco
Prior art keywords
change factor
adrenal hormone
hormone change
subject
adrenal
Prior art date
Application number
MA35039A
Other languages
Arabic (ar)
English (en)
Inventor
Qi-Ying Hu
Gary Ksander
Erik Meredith
Lauren G Monovich
Julien Papillon
Christoph Schumacher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33904(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33904B1 publication Critical patent/MA33904B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé de traitement d'une maladie ou d'un trouble caractérisé par des taux accrus de l'hormone du stress et/ou des taux diminués d'hormones androgènes dans un sujet. Ce procédé comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé représenté par la formule (i) : dans laquelle n vaut 1 ou 3 ; r représente l'hydrogène ou c(o)n(r
MA35039A 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes MA33904B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14
PCT/US2011/021100 WO2011088188A1 (fr) 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes

Publications (1)

Publication Number Publication Date
MA33904B1 true MA33904B1 (fr) 2013-01-02

Family

ID=43735742

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35039A MA33904B1 (fr) 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes

Country Status (34)

Country Link
US (2) US8609862B2 (fr)
EP (2) EP3527208A1 (fr)
JP (4) JP5602250B2 (fr)
KR (1) KR101412206B1 (fr)
CN (2) CN105440038A (fr)
AU (1) AU2011205290C1 (fr)
BR (1) BR112012017458B1 (fr)
CA (1) CA2786443C (fr)
CL (1) CL2012001961A1 (fr)
CY (2) CY1121320T1 (fr)
DK (1) DK2523731T3 (fr)
ES (1) ES2707596T3 (fr)
HR (1) HRP20190064T1 (fr)
HU (2) HUE041967T2 (fr)
IL (1) IL220804A0 (fr)
LT (2) LT2523731T (fr)
LU (1) LUC00159I2 (fr)
MA (1) MA33904B1 (fr)
ME (1) ME03371B (fr)
MX (2) MX354022B (fr)
NL (1) NL301043I2 (fr)
NO (1) NO2020012I1 (fr)
NZ (1) NZ601077A (fr)
PH (1) PH12012501422B1 (fr)
PL (1) PL2523731T3 (fr)
PT (1) PT2523731T (fr)
RS (1) RS58234B1 (fr)
RU (1) RU2598708C2 (fr)
SG (1) SG182393A1 (fr)
SI (1) SI2523731T1 (fr)
TN (1) TN2012000352A1 (fr)
TR (1) TR201900515T4 (fr)
WO (1) WO2011088188A1 (fr)
ZA (1) ZA201205058B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
US9078886B2 (en) 2010-06-16 2015-07-14 Embera Neurotherapeutics, Inc. Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
AR086665A1 (es) 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
EP2757882B1 (fr) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase
EP2757884B1 (fr) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Composés pyrazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
EP2757883B1 (fr) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
PL2804863T3 (pl) * 2012-01-17 2016-06-30 Novartis Ag Nowe postacie i sole inhibitora syntazy aldosteronowej lub aromatazy dihydropirolo[1,2-c]imidazolilu
JP6383352B2 (ja) * 2012-04-12 2018-08-29 ノバルティス アーゲー ソマトスタチンアナログの１１ベータ−水酸化酵素阻害剤との組合せ
JP6496246B2 (ja) 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
TWI707682B (zh) 2014-07-07 2020-10-21 瑞士商瑞科戴迪股份有限公司 醫藥劑型
WO2016048984A1 (fr) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Méthodes et compositions pour le traitement du syndrome de cushing basées sur le 2s,4r kétoconazole
AU2016210899B2 (en) 2015-01-29 2019-03-07 Recordati Ag Process for the production of condensed imidazolo Derivatives
WO2016164476A2 (fr) 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Polythérapie pour le traitement de troubles liés à un excès de production de cortisol
WO2016209929A1 (fr) * 2015-06-22 2016-12-29 Embera Neurotherapeutics, Inc Compositions et procédés pour le traitement de troubles d'utilisation de substances, d'accoutumance, et de troubles psychiatriques
US11179377B2 (en) 2017-03-10 2021-11-23 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
IL157363A0 (en) * 2001-02-16 2004-02-19 Aventis Pharma Inc Novel heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
WO2007105203A2 (fr) 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
CN101448832A (zh) * 2006-05-26 2009-06-03 诺瓦提斯公司 醛固酮合酶和/或11β-羟化酶抑制剂
EP1886695A1 (fr) 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
CN101506216A (zh) * 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
KR20090090395A (ko) * 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EP2095819A1 (fr) * 2008-02-28 2009-09-02 Maastricht University Dérivés de N-benzyle imidazole et leur utilisation comme inhibiteurs de l'aldosterone synthase
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
PL2804863T3 (pl) * 2012-01-17 2016-06-30 Novartis Ag Nowe postacie i sole inhibitora syntazy aldosteronowej lub aromatazy dihydropirolo[1,2-c]imidazolilu
JP6383352B2 (ja) * 2012-04-12 2018-08-29 ノバルティス アーゲー ソマトスタチンアナログの１１ベータ−水酸化酵素阻害剤との組合せ

Also Published As

Publication number Publication date
NO2020012I1 (no) 2020-06-09
US9434754B2 (en) 2016-09-06
PH12012501422B1 (en) 2018-09-12
ZA201205058B (en) 2014-04-30
JP6425688B2 (ja) 2018-11-21
ME03371B (fr) 2020-01-20
JP6181610B2 (ja) 2017-08-16
TN2012000352A1 (en) 2014-01-30
ES2707596T3 (es) 2019-04-04
JP2015013859A (ja) 2015-01-22
NL301043I1 (nl) 2020-06-17
SI2523731T1 (sl) 2019-02-28
RS58234B1 (sr) 2019-03-29
CN105440038A (zh) 2016-03-30
PL2523731T3 (pl) 2019-04-30
JP2018150326A (ja) 2018-09-27
DK2523731T3 (en) 2019-02-04
MX354022B (es) 2018-02-08
KR101412206B1 (ko) 2014-06-25
CN102711916A (zh) 2012-10-03
US20140171392A1 (en) 2014-06-19
EP3527208A1 (fr) 2019-08-21
LT2523731T (lt) 2019-02-11
TR201900515T4 (tr) 2019-02-21
CA2786443C (fr) 2018-12-11
LTC2523731I2 (lt) 2022-05-10
NL301043I2 (nl) 2020-07-06
US20120295888A1 (en) 2012-11-22
CA2786443A1 (fr) 2011-07-21
BR112012017458A2 (pt) 2017-12-19
BR112012017458B1 (pt) 2020-10-20
JP2013517280A (ja) 2013-05-16
HUS2000018I1 (hu) 2020-07-28
LTPA2020512I1 (lt) 2020-07-27
HUE041967T2 (hu) 2019-06-28
WO2011088188A1 (fr) 2011-07-21
PH12012501422A1 (en) 2012-10-22
NZ601077A (en) 2014-07-25
CY1121320T1 (el) 2020-05-29
CL2012001961A1 (es) 2013-03-22
JP5602250B2 (ja) 2014-10-08
EP2523731A1 (fr) 2012-11-21
IL220804A0 (en) 2012-08-30
EP2523731B1 (fr) 2018-10-24
US8609862B2 (en) 2013-12-17
PT2523731T (pt) 2019-01-21
CY2020018I1 (el) 2020-11-25
RU2598708C2 (ru) 2016-09-27
KR20120116482A (ko) 2012-10-22
CY2020018I2 (el) 2020-11-25
AU2011205290A1 (en) 2012-08-02
JP2017002063A (ja) 2017-01-05
AU2011205290B2 (en) 2014-06-26
CN102711916B (zh) 2015-09-02
HUS000508I2 (hu) 2021-03-29
RU2012134510A (ru) 2014-02-20
LUC00159I2 (fr) 2021-07-06
HRP20190064T1 (hr) 2019-03-08
MX2012008212A (es) 2012-08-03
AU2011205290C1 (en) 2014-11-06
LUC00159I1 (fr) 2020-06-16
SG182393A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
MA33904B1 (fr) Utilisation d'un agent de modification d'hormones surrénaliennes
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MA32108B1 (fr) Derives d'indazole
MA37958B1 (fr) Pde9i ayant un squelette imidazo pyrazinone
TNSN08337A1 (fr) Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
MA33923B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA51837B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
JP2011500813A5 (fr)
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
PH12021551483A1 (en) Fxr (nr1h4) modulating compounds
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
MA33924B1 (fr) Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MY163327A (en) Imidazole derivatives as pde10a enzyme inhibitors
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA60154A1 (fr) Inhibiteurs de line-1 pour traiter une maladie
MA38659B1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate